光滑念珠菌的生物学、流行病学以及耐药机制研究进展

随着HIV感染患者的增多、器官移植、放疗化疗及抗真菌药物的广泛使用,近年来全世界范围内念珠菌感染趋势发生了明显变化,除白念珠菌外,光滑念珠菌在临床上的检出率逐年增加,在部分国家和地区已成为第二常见的侵袭性念珠菌。光滑念珠菌临床分离株通常对一线抗真菌药物高度耐药,由于目前治疗策略匮乏,其造成的系统感染死亡率可高达50%。为了进一步加深人们对光滑念珠菌的认识,研发遏制其感染的诊疗策略,本文综述了近年来光滑念珠菌的流行病学、毒力因子以及耐药机制等方面的进展,为国内同行深入探究其耐药特性和致病机理提供参考。

Research advances of biology,epidemiology and mechanism of drug resistance in Candida glabrata

With the widespread of HIV infection, increased organ transplants and chemo/radiotherapy, and wide application of antifungal drugs, the worldwide trend of Candida infection has changed significantly in recent years. In addition to Candida albicans, the infection rate of Candida glabrata increases gradually by years, and it has become the second most common Candida species of invasive infections in some countries and regions. Clinical isolates of C. glabrata are often highly resistant to fluconazole and cause systemic infection with a mortality of up to 50% due to the lack of effective treatment strategies. To improve the understanding of C. glabrata biology, this review describes research progress on the epidemiology, multiple virulence factors, and drug resistance mechanisms of this pathogen made in the past decade. We hope it would benefit the community to further explore the multiple drug resistance and pathogenic mechanisms.